newswire, breaking news for marijuana, cannabis and hemp stocks

Wednesday 18 November 2020

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 497 (NASDAQ: $SAMA), (CSE: $DELC.C), (TSXV: $PCLO.V), (TSXV: $N.V)

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 497 (NASDAQ: $SAMA), (CSE: $DELC.C), (TSXV: $PCLO.V), (TSXV: $N.V)

Today's podcast sponsored by Cannabis Suisse Corp. (OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in Switzerland


Delta, Kelowna, BC, November 18, 2020 ( Newswire), a global news source covering leading sectors including marijuana and hemp stocks and its potcast site,  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.


Listen to the podcast:


Read this in full at


Hear Investor ideas cannabis potcast on iTunes  


Today’s podcast overview/transcript:


Good afternoon and welcome to another episode of "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.


Today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's facilities for producing cannabis are based in Dietikon, Switzerland, and contain the art surveillance equipment to enable an around the clock webcast. Cannabis Suisse grows high quality, organic cannabis with sustainable, all-natural principles. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse proprietary trademarked MoldStandard is a quantitative microbiology method for analyzing yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary trademarked CannaMec is a method for quantifying and removing residual solvents during packaging and storage of CBD products. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.


In today’s podcast we will be looking at a few private and public company announcements.



Clever Leaves International Inc., a leading multi-national operator and licensed producer of pharmaceutical-grade cannabinoids, provided an update on their current international footprint by announcing successful exportation of cannabis products to 14 different countries and 5 continents as of Q4 of 2020. The products range from raw materials, including active pharmaceutical ingredients (APIs) and semi-finished products, including white label products.


Clever Leaves’ international network highlights the Company’s ability maintain important partnerships with regulatory agencies and governments as well as the ability to navigate pandemic-related supply chain setbacks. In compliance with all cannabis regulations in the countries served, the Company’s portfolio of products has been exported to Australia, Brazil, Canada, Chile, the Czech Republic, Germany, Israel, Netherlands, Perú, Poland, Spain, South Africa, the United Kingdom, and the United States.


“Most of the international cannabis industry functions like a pharmaceutical channel requiring significant investments of time and focus by both a supplier such as Clever Leaves and its commercial partners throughout the world. Success depends on navigating nascent but strict regulatory systems, and relationships often require initial small batch or sample shipments and validation before larger partnerships can emerge. COVID-19 has introduced new challenges even when it comes to basic transportation logistics. These milestones across our export network strengthen our ability to deliver value to our business partners and to patients around the world,” said Kyle Detwiler, CEO of Clever Leaves.


“The resilience, professionalism, and creativity in times of setback, have been critical to the success of our team to navigate complex regulatory frameworks and to meet customers' deadlines during a time of unparalleled logistical restrictions. Additionally, we are grateful to work in partnership with local regulatory agencies and logistics service providers who share the same goal to bring high-quality medical cannabis products to patients and are committed to the advancement of the global cannabis market,” said Andrés Fajardo, President of Clever Leaves.


The Company was granted their EU GMP certification for cannabis extracts in July 2020, establishing Clever Leaves’ facilities in Colombia as the first and only operation to be granted EU GMP certification in Latin America and one of a select few in the world. The certification, which is generally required to import medical cannabis products into the European Union, allows Clever Leaves to produce API, semi-finished and finished products to be distributed in pharmaceutical channels. Additionally, in August 2020, Clever Leaves was granted a provisional license in Portugal from Infarmed, the Portuguese health authority that allows Clever Leaves to cultivate, import and export dry flower for medicinal and research purposes.


Clever Leaves recently announced that it amended its definitive agreement with Schultze Special Purpose Acquisition Corp. (NASDAQ: SAMA), pursuant to which a newly formed holding company, Clever Leaves Holdings Inc. will acquire SAMA and Clever Leaves. The transaction is expected to close in the fourth quarter of 2020, with Holdco anticipated to become a Nasdaq-listed public company trading under the ticker symbol “CLVR".


Delic Holdings Inc., a psychedelic-focused media, e-commerce and event company, announced that effective at market open today, the Company will begin trading on the Canadian Securities Exchange under the ticker symbol (CSE: DELC).


Jackee Stang, CEO of DELIC comments “Canada has consistently shown leadership in helping cannabis and now psychedelics emerge from false stigmas. Canada was the first G7 country to legalize cannabis, and as psychedelics further gain ground on what may appear as false stigmas, the health and wellness sector will only grow. As such, the DELIC community is deeply proud to be a part of the Canadian Securities Exchange. We started DELIC to mainstream the psychedelic conversation, advocate for cognitive freedom and ultimately see an end to the War on Drugs.”


Ms. Stang continued, “As the first ever psychedelic wellness corporation, it is our mission to open the doors of psychedelic healing to the masses. We decided to take DELIC public because we believe that psychedelic wellness should be open to everyone... All people from diverse backgrounds and varied life experiences. DELIC is the first ever psychedelic wellness company designed to disrupt the status quo by diversifying our operations, maintaining sensible messaging and intentionally avoiding dogmatic practices or binary rhetoric. We believe in being pragmatic and maintaining a clear-headed approach as the psychedelic sector continues to build.”


In conjunction with the previously-announced business combination with Molystar Resources Inc., DELIC raised $3,475,500 through a non-brokered private placement offering.


On November 17, 2020, the Company issued an aggregate of 3,450,000 options to directors, officers and certain advisors pursuant to the Company’s share compensation plan — each with an exercise price of $0.25, vesting as to 1/3 of such options on each of the 6, 12 and 18-month anniversaries, and expiring in three years.


PharmaCielo Ltd.  (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced that it has delivered its first commercial shipment of medicinal grade CBD isolate to a well-established, bulk distributor and white label manufacturer based in the U.K., with sales and distribution operations in the U.K., and the E.U.


In addition, the Company has reached an interim sales agreement with the Customer, lasting until the end of Q1-2021, at which point PharmaCielo expects to have submitted a Novel Foods authorization application for its range of CBD extracts. The interim, renewable agreement enables continued shipments for the remainder of 2020 and calls for the shipment of up to 1,000 kg of CBD Isolate and Broad-Spectrum CBD based on the Customer's specifications, during Q1-2021. With submission of the Novel Foods authorization application prior to March 31, the Company expects to be in a position to subsequently expand both volume and exported consumable product types during fiscal 2021 in accordance with regulatory requirements.


"As consumer demand for health and wellness products containing cannabinoids continues to expand, PharmaCielo is well-positioned to deliver a portfolio of medicinal-grade extracts at scale to serve the needs of global CBD-market facing providers," said David Attard, CEO of PharmaCielo Ltd. "Having focused to date on building a world-class infrastructure in Colombia as well as developing a robust product portfolio, we are ideally positioned to become the supplier of choice for large volume B2B sales globally. 2021 will be a very exciting year for the Company as we significantly expand global export volumes, and the addition of the Customer's relationships throughout international markets long-term, including the U.K. and E.U., support this focus."


Distribution of CBD products by the Company under its interim sales agreement with the Customer is subject to the approval of the TSX Venture Exchange (the "TSXV").


Namaste Technologies Inc. (TSXV: N) (OTC: NXTTF), a leading platform for cannabis products, accessories, and education, announced that it has entered into a share purchase agreement to acquire the remaining 49% interest in CannMart Labs Inc., an applicant for a processing licence under the Cannabis Act (Canada) for cannabis extraction activities.

Transaction Highlights:

       Namaste to acquire remaining 49% of CannMart Labs to 100% ownership

       CannMart Labs facility in Ontario is completed for BHO extraction using leading extraction technology, making it one of only a few facilities in Canada with such capabilities

       Application in final phase for a processing licence from Health Canada

       Set to produce in-house branded Cannabis 2.0 products for medical channel customers at and recreational customers across Canada through sister company CannMart Inc.'s network of provincial sales partners

       Cannabis 2.0 products initially planned include shatter and live resin with capabilities to expand future distillate product offerings to vape cartridges, gel capsules, tinctures and edibles


In May 2018, Namaste acquired a 51% interest in CannMart Labs and agreed to finance the construction of its facility in Etobicoke, Ontario, a purpose-built oil extraction facility which incorporates a leading extraction technology facility designed to meet EU Good Manufacturing Practice (EU-GMP) certification requirements.


"Acquiring the remaining interest in CannMart Labs is another important milestone achieved in establishing Namaste as a leading company within the Canadian cannabis sector," said Meni Morim, Chief Executive Officer of Namaste. "CannMart Labs is in the final stage of its application for an important processing licence from Health Canada. It has installed state-of-the-art extraction technology in its facility, which when granted a licence, will be able to produce an array of cannabis products including shatter and live resin, as well as future distillate products such as vape cartridges, gel capsules, tinctures and edibles."


Mr Morim added: "This transaction is advantageous to Namaste shareholders as the Vendors will continue to provide management services and will receive earn-out payments in the form of Namaste common shares or cash only upon the successful achievement of certain revenue and gross profit targets and if the targets are met, the cash payment option allows Namaste to minimize dilution associated with the acquisition. We are working hard towards receiving our processing licence from Health Canada and look forward to producing in house branded Cannabis 2.0 products, for our medical channel customers at and recreational consumers across Canada through our network of provincial sales partners."


Under the terms of the proposed transaction (the "Proposed Transaction"), Namaste will acquire the remaining 49% interest of CannMart Labs from MKD Holdings Inc. and JLLS Holdings Inc. in exchange for a purchase price of $4,034,000. A first tranche of the Purchase Price of $1,608,500 will be paid to the Vendors in common shares of Namaste issued at a deemed price equal to the seven day volume weighted average price of Namaste's common shares on the TSX Venture Exchange (the "VWAP") on the closing date of the Proposed Transaction. The remaining Purchase Price of $2,425,500 is payable to the Vendors in equal tranches over the next nine fiscal quarters beginning on the fiscal quarter ending February 28, 2021, at the VWAP on the date of issuance required within 5 days of the end of the applicable fiscal quarter.


Once again, today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.


Investor ideas reminds all listeners to read our disclaimers and disclosures on the website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.


Learn more about our cannabis podcasts at



Hear Investor ideas cannabis potcast on iTunes  


Hear the investor ideas potcast on Spotify

To hear more podcasts visit: podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.


Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708


About - News that Inspires Big Investing Ideas is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Cannabis Suisse Corp. (OTC: CSUI),is a paid featured company on More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Global investors must adhere to regulations of each country. Please read privacy policy:


Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.


Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at


Follow us on Twitter

Follow us on Facebook

Follow us on YouTube

Download our Mobile App for iPhone and Android 

Join our Investor Club



800 665 0411




Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

No comments:

Post a Comment

Study shows Cannabis terpenes may relieve chemotherapy-induced neuropathic pain

Study shows Cannabis terpenes may relieve chemotherapy-induced neuropathic pain : Study shows Cannabis terpenes may relieve chemotherapy-ind...